Clinical Trial Update: Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and antiviral activity of inarigivir soproxil plus tenofovir alafenamide in adults with chronic hepatitis B; study terminated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Inarigivir Soproxil (GS-9992) (inarigivir soproxil)
• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis B | Phase 2 | Status: TERMINATED | Results posted: 2022-04-04